Revolution Medicines (RVMDW) Enterprise Value (2019 - 2026)
Revolution Medicines (RVMDW) posted quarterly Enterprise Value of -$1.9 billion for Q1 2026, up 9.25% year-over-year from -$1.7 billion in Q1 2025, and up 5.81% quarter-over-quarter from -$2.0 billion in Q4 2025.
Revolution Medicines (RVMDW) Enterprise Value (2019 - 2026) Analysis & Trends
Revolution Medicines' Enterprise Value history runs 8 years deep, the most recent figure standing at -$1.9 billion for Q1 2026.
- In Q1 2026, Enterprise Value rose 9.25% year-over-year to -$1.9 billion; the TTM figure through Mar 2026 stood at -$1.9 billion (up 9.25% YoY), while the FY2025 annual figure was -$2.0 billion, up 11.52% from the prior year.
- Enterprise Value for Q1 2026 stood at -$1.9 billion, up from -$2.0 billion in the prior quarter.
- The five-year high for Enterprise Value was -$461.4 million in Q2 2022, with the low at -$2.3 billion in Q4 2024.
- The 5-year median for Enterprise Value is -$1.6 billion (2024), against an average of -$1.4 billion.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value increased 28.61% in 2022, then plunged 187.31% in 2023.
- Revolution Medicines' Enterprise Value stood at -$644.9 million in 2022, then slumped by 187.31% to -$1.9 billion in 2023, then slipped by 23.55% to -$2.3 billion in 2024, then climbed by 11.52% to -$2.0 billion in 2025, then gained by 5.81% to -$1.9 billion in 2026.
- Business Quant data shows RVMDW's Enterprise Value at -$1.9 billion in Q1 2026, -$2.0 billion in Q4 2025, and -$1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Revolution Medicines | 2.59 Bn | 2.59 Bn | - | -3.94 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.94 Bn |
| Mar 31, 2026 | -1.91 Bn |
| Dec 31, 2025 | -2.03 Bn |
| Sep 30, 2025 | -1.93 Bn |
| Jun 30, 2025 | -2.14 Bn |
| Mar 31, 2025 | -2.10 Bn |
| Dec 31, 2024 | -2.29 Bn |
| Sep 30, 2024 | -1.55 Bn |
| Jun 30, 2024 | -1.59 Bn |
| Mar 31, 2024 | -1.70 Bn |
| Dec 31, 2023 | -1.85 Bn |
| Sep 30, 2023 | -813.20 Mn |
| Jun 30, 2023 | -909.49 Mn |
| Mar 31, 2023 | -909.80 Mn |
| Dec 31, 2022 | -644.94 Mn |
| Sep 30, 2022 | -655.01 Mn |
| Jun 30, 2022 | -461.43 Mn |
| Mar 31, 2022 | -518.75 Mn |
| Dec 31, 2021 | -577.05 Mn |
| Sep 30, 2021 | -608.66 Mn |